Neuroton

Quick links to important sections

Neuroton

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neuroton

What is Neuroton? A Quick Overview

Property Description
Active Ingredient Citicoline (CDP-Choline)
Pharmacological Class Nootropic, Neuroprotectant
Primary Forms Solution for injection, Tablets, Oral Solution
General Purpose Supports brain cell structure and metabolism
Origin Synthesized analog of an endogenous compound

What is Neuroton and What Class of Medicine is It?

Neuroton is a medicinal entity whose primary active ingredient is Citicoline, a compound chemically identical to the essential endogenous biochemical, Cytidine 5'-diphosphocholine (CDP-Choline). It is clinically recognized as a potent neuroprotectant and a cerebral metabolic enhancer. Within standard pharmacological classifications, Citicoline is categorized as a nootropic and a psychostimulant.

As a single-active-ingredient product, its function is directly attributed to the Citicoline component. This compound is typically available as a prescription-only medicine in many healthcare systems, reflecting its established pharmacological role in supporting the central nervous system. This unique mechanism of directly contributing structural components to the cell membrane is clinically recognized for supporting recovery following periods of neural stress or cognitive decline.


Composition, Origin, and Available Forms of Citicoline

The core of Neuroton’s composition is Citicoline, an active substance that serves as a precursor essential for the biosynthesis of phospholipids—vital for neuronal membrane structure. Citicoline plays a key role in the biosynthesis of these structural components, which are essential for cell integrity. This biological role supports the medicine’s ability to provide necessary components to help maintain brain cell health. Although Citicoline is often chemically synthesized for pharmaceutical use, its molecular structure is identical to the natural CDP-Choline found within the human body, classifying it as an endogenous compound analog.

Citicoline is supplied in several common pharmaceutical preparations, including a sterile aqueous solution for injection (for parenteral administration) and solid tablets or liquid oral solution preparations for oral ingestion. These varied forms ensure the active ingredient is accessible for systemic delivery, depending on the required therapeutic approach.


What is the General Purpose of This Neuroprotectant?

The general purpose of a Citicoline-based product is to act as a restorative agent that sustains the health and functional integrity of brain cells. It achieves this by providing the necessary chemical building blocks (choline and cytidine) to support the continual neuronal membrane repair process.

This fundamental action translates to a broad aim of promoting metabolic efficiency and neurotransmitter support within the central nervous system. It is often used to support cognitive function in older adult patient groups, as it is intended to help maintain the resilience and overall functional vitality of cognitive pathways. By strengthening the structural basis and chemical environment of neural tissues, the medicine is used to promote structural and metabolic stability.

Regulatory References

  1. NIH National Library of Medicine

What side effects are possible with Neuroton?

Possible side effects and safety information

Official regulatory documents classify the possible adverse effects of Citicoline (Neuroton) primarily within the Very Rare frequency category, meaning they affect less than 1 in 10,000 treated patients. Safety information is organized by the body systems where effects may occur, which is the standard procedure in regulatory communication.

Adverse Reaction Classification

The documented adverse reactions are categorized into several System-Organ Classes. These include Nervous System Disorders, which may involve headache or dizziness; Gastrointestinal Disorders, such as nausea, vomiting, or gastric pain; and Vascular Disorders, which list changes like arterial hypotension or hypertension. Reactions related to the immune system, such as rash or hives (Urticaria), are also listed in official labeling.

Safety Considerations and Restrictions

High-level safety constraints define the conditions where this medicine should not be used. Citicoline is formally contraindicated in individuals with a known hypersensitivity to the active ingredient or any component of the product. It is also restricted in patients who have a diagnosis of hypertonia of the parasympathetic nervous system.

For specific patient populations, safety status is often defined as not clinically established. Regulatory documents state that the safety and efficacy of Citicoline have not been established during pregnancy and lactation. Consequently, its use in these situations is restricted to those instances where the potential therapeutic benefits are judged to outweigh the documented risks, reflecting the official regulatory boundary for safety in these groups.

Overdose and Emergency Response

The official regulatory documentation for Neuroton (Citicoline) establishes an overdose profile characterized by very low toxicity in humans. Due to this high safety margin, specific clinical manifestations of acute intoxication are officially described as unlikely, even following accidental ingestion exceeding therapeutic use.

Element Official Regulatory Assessment
Documented Manifestations Low toxicity profile; intoxication appearance is unlikely. No severe, specific clinical symptoms are typically listed in the overdose section.
Emergency-Response Patients must seek immediate medical attention or consult a physician following any accidental or significant ingestion.
Antidote No specific antidote is known or available for overdose management.
Management Measures Treatment is to be entirely symptomatic and supportive.

Official Overdose Statements

  • The required management procedure in case of overdose is to provide only symptomatic and supportive treatment.
  • The substance is classified as having very low toxicity, which minimizes the risk of severe or life-threatening outcomes.
  • Regulatory guidance specifies that patients must contact emergency services or a healthcare professional for assessment following accidental ingestion.

This regulatory framework defines the overdose structure by establishing a low-risk scenario, necessitating non-specific supportive care. The mandated requirement to seek help ensures medical professionals can assess the situation and apply the specified symptomatic measures.

Therapeutic Uses of Neuroton

Neuroton (Citicoline) is used in situations involving certain distressing symptoms. Its application centers on providing symptomatic relief in areas where functional stability may become affected. It is commonly used across conditions presenting with episodic or fluctuating manifestations, relevant in clinical settings marked by heightened symptoms of stroke, head injury, Parkinson's disease, and cognitive impairment.

In clinical settings, it is applied in situations that involve acute or unstable symptom patterns, and helps address symptom clusters that may become intense or disruptive, such as memory loss, dizziness, or poor concentration. The supportive therapy is relevant for managing symptoms that interfere with daily comfort. The medication may be part of symptomatic management in situations where functional stability becomes affected, which provides support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods.


Quick Fact: Relief for Cognitive Impairment Neuroton is commonly used across conditions presenting with heightened symptoms, and may assist with managing the cluster of symptoms involving memory loss and attention deficits in older adults, which helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. FDA Philippines Verification Portal

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Neuroton (Citicoline) — Official Regulatory Information


Eligibility Scope

Category Regulatory Statement (Strictly Label-Based)
Populations for whom use is allowed Use is established in the Adult and Older Adult populations for the approved indications.
Populations for whom use is not recommended Children, due to limited experience and the status of use being not established in regulatory documents.
Populations for whom use is contraindicated Patients with known hypersensitivity to any component of the formulation. Patients with hypertonia of the parasympathetic nervous system.
Age-related eligibility rules Pediatric use is not definitively established; administration is restricted and must be conditional on the expected benefits outweighing any potential risk.
Condition-specific eligibility rules Contraindicated in a specific neurological condition: Hypertonia of the parasympathetic nervous system.
Pregnancy and lactation eligibility status Conditional status: Use during pregnancy and lactation is permitted only when benefits justify the potential risks because safety evidence is insufficient.
Eligibility-related restrictions Patients with persistent intracranial hemorrhage are subject to a conditional restriction requiring specific care, such as reduced dosage or very slow administration.

Eligibility Classifications (High-Level)

Classification Regulatory Basis
Eligibility severity classification Absolute Prohibition (Contraindication) or Conditional Use (Risk/Benefit Assessment Required).
Eligibility-context constraints Comorbidity-linked constraint (Parasympathetic Hypertonia), Physiological state constraint (Pregnancy/Lactation), and Age-related data constraint (Pediatrics).

Resulting Eligibility Structure

Official eligibility statements:

  • Use is contraindicated in patients with a known hypersensitivity to the active substance or excipients.
  • Prohibited in patients presenting with hypertonia of the parasympathetic nervous system.
  • Use is restricted in pregnant and breastfeeding women; it must only proceed if the potential benefit justifies the potential risk.
  • Use in children is considered limited, and the medicine is only prescribed when the expected benefits outweigh any potential risk.

Connection to the overall eligibility profile: Official regulatory documents strictly define Neuroton's eligibility by establishing two primary exclusion categories: absolute contraindications based on hypersensitivity or specific nervous system hypertonia, and conditional use status for populations (children, pregnant/lactating women) or specific acute conditions where safety data is insufficient or requires special monitoring.

What should I know about interactions with other medicines?

Neuroton (gabapentin) can interact with several other medications and products, primarily by increasing the risk of central nervous system (CNS) depression, which can cause excessive drowsiness, dizziness, and respiratory difficulties. Before starting Neuroton, it is essential to inform your healthcare provider about all prescription and over-the-counter (OTC) medicines, vitamins, and herbal supplements you are currently taking.

Medications that Increase Sedation Risk

Combining Neuroton with other medications that slow brain activity may increase the risk of serious side effects, including severe drowsiness and dangerously slowed breathing. Caution and close monitoring are necessary when Neuroton is taken alongside:

  • Opioid Pain Medications: Such as morphine, hydrocodone, or tramadol. This combination significantly increases the risk of sedation, respiratory depression, and potentially life-threatening overdose.
  • Anxiety and Sleep Medications: Including benzodiazepines (e.g., alprazolam, lorazepam) and non-benzodiazepine hypnotics (e.g., zolpidem).
  • Antihistamines: Particularly those that cause drowsiness (e.g., diphenhydramine).
  • Other CNS Depressants: This includes certain antidepressants, antipsychotics, and muscle relaxants.

Interactions Affecting Neuroton Absorption

Antacids that contain aluminum and/or magnesium may reduce the absorption of Neuroton, potentially making it less effective. To minimize this interaction, it is recommended to take Neuroton at least two hours after taking an aluminum- or magnesium-containing antacid.

Alcohol and Herbal Products

Alcohol should be avoided while taking Neuroton as it can significantly enhance the drug's side effects, leading to severe dizziness and impaired concentration. Herbal products or supplements known to cause drowsiness, such as kava or valerian root, should also be used with caution, as they may worsen Neuroton's sedative effects.

Mechanism of Action

Neuroton modulates the Wnt signaling pathway, which participates in bone tissue regulation. The primary mechanism of action involves the selective antagonism of the Sclerostin (SOST) protein. Binding to Sclerostin results in a reduction of Wnt pathway inhibition, thereby permitting increased osteoblast differentiation and activity. This molecular cascade elevates the rate of bone matrix synthesis. Additionally, Neuroton indirectly alters the ratio of bone formation to bone resorption, exhibiting an effect on osteoclast activity. This dual action modulates both bone formation and resorption processes by targeting an upstream regulator of bone cell function. This activity modifies cellular signaling to favor the synthetic phase of the remodeling cycle, influencing the physiological turnover of the tissue structure.

Dosage and Administration Information

How Neuroton (Citicoline) is Used: Administration and Dosing

Neuroton, which contains the active ingredient Citicoline, is administered according to principles that define the approved routes and dosage ranges. These parameters ensure consistent use as established within professional healthcare standards.

Administration Routes and Forms

The medicine is approved for systemic delivery through both oral and parenteral routes.

  • Oral Use: Available as tablets, capsules, or oral solutions. These forms may generally be taken with or without food.
  • Parenteral Use: Administered via Intravenous (IV) or Intramuscular (IM) injection, utilizing a sterile solution form.

Standard Adult Dosing and Frequency

The established adult total daily dosage typically ranges from 500 mg to 2000 mg per day. This dose is usually administered once daily or divided into multiple doses throughout the day, depending on the required use pattern.

Usage Pattern Typical Dose Range Maximum Daily Dose Frequency
Standard Adult Dose 500 mg to 1000 mg 2000 mg Once daily or in divided doses

Procedural and Population Constraints

Official labeling includes constraints for proper administration. When given as a direct IV injection, the dose is administered very slowly (over at least 3 to 5 minutes) to adhere to procedural guidelines. Regarding age-specific instructions, standard prescribing information indicates that no dose adjustment is typically required for older adults.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Neuroton (Citicoline)


Evidence for Use in Acute Ischemic Stroke

Research has explored the use of Neuroton in studies examining outcomes after an ischemic stroke—a condition where symptoms are often acute or disruptive. Researchers conducted short-term randomized controlled trials (RCTs) and complex analyses of patient data, primarily involving adults in the immediate phase following the stroke event. These studies monitored outcomes related to functional status and disability using standardized scales, as well as assessments of the severity of the neurological deficit.

Findings were mixed across the largest multi-center trials; some trials described measured patterns in functional status, while others reported no distinct patterns when compared to placebo. The consistency of outcomes is limited, as not all major, high-quality RCTs demonstrated uniform patterns of difference in global functional measures.


Evidence for Use in Cognitive Impairment

Research examined the administration of Neuroton in older adults who experienced various degrees of cognitive impairment, such as age-associated memory decline. The studies included RCTs and Systematic Reviews that explored changes in overall global cognitive status and specific domains, including attention and verbal memory. These trials typically observed responses over defined time intervals, often ranging from three to twelve months.

Some trials described measured changes across various cognitive testing scores. This research highlights changes measured during the study period and contributes to understanding symptom patterns. However, the overall evidence quality varies across studies, with some systematic reviews concluding that the overall certainty remains low for these uses. The consistency of measured differences is not fully established.


Unanswered Questions and Research Limitations

The available evidence base has several limitations that define the research landscape:

  • Findings were mixed across some of the largest clinical trials, particularly for stroke and TBI.
  • Follow-up durations were limited in many controlled studies, which means that long-term effects are not fully established.
  • Comparative evidence is lacking for many populations, and the results apply only to the populations studied and the specific conditions under which they were conducted.

Key Studies & References

  1. Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT) (Phase 3 RCT, primary trial for TBI section)
  2. CITICOLINE EFFICIENCY ON COGNITIVE FUNCTION: A SYSTEMATIC REVIEW (Assessing MMSE, memory, and attention)
  3. Effect of citicoline adjuvant therapy on mild cognitive impairment in Parkinson's disease (PD-MCI study)
  4. Citicoline (CDP-choline) - Alzheimer's Drug Discovery Foundation (Evidence Summary)

Frequently Asked Questions (FAQ)

Common questions about Neuroton (FAQ)

Q: What is the main reason doctors prescribe Neuroton?

A: Official product information describes Neuroton's approved uses, which include supporting patients during the acute and recovery phases after a cerebral infarction, commonly known as a stroke. The medicine is also indicated for managing cognitive dysfunction associated with degenerative or cerebrovascular disease. Furthermore, it is used for cerebral insufficiency resulting from certain types of head trauma.

Q: Is Neuroton used for any conditions other than the main ones listed?

A: Regulatory documents strictly define the conditions for which Neuroton has been officially approved. These approved indications are the primary focus of the official product labeling. Uses of the medicine that are not specifically listed on the official label are not detailed in the authorized regulatory documents.

Q: How long does it typically take for Neuroton to start having an effect?

A: Studies that examine how the body processes the drug, known as pharmacokinetic studies, show that Neuroton is quickly absorbed after it is taken orally. Studies report that the concentration of the active ingredient in the blood has been observed to peak at approximately one hour after the dose, with a second peak observed around 24 hours later.

Q: If I miss a dose of Neuroton, what should I do?

A: Official patient information states that a double dose should not be taken to compensate for a missed amount. Instead, the guidance is to continue with the next scheduled dose at the usual time.

Q: Is Neuroton a controlled substance?

A: Official drug classification systems categorize the active ingredient, Citicoline, as both a nootropic and a psychostimulant. While these classifications reflect its effect on the central nervous system, official regulatory documents generally do not list it as a federally controlled substance.

Q: Can Neuroton cause weight gain or weight loss?

A: The official safety information for Neuroton does not list weight gain or weight loss as documented side effects. Clinical research has specifically investigated the potential for changes in weight status while taking the medicine. Some evidence indicates that patients in these studies did not experience a significant change in weight.

Q: Does Neuroton interact with common over-the-counter pain relievers?

A: Regulatory drug interaction checkers have specifically reviewed the combination of the active ingredient Citicoline with common non-opioid pain relievers. Information indicates that no known interaction was found when combined with a widely used over-the-counter pain reliever like Paracetamol (Acetaminophen).

Q: Is Neuroton safe to take every day for a long time?

A: Studies have examined the use of the active ingredient for defined time periods, with some research focusing on administration for up to 12 weeks. One official source indicates that the medicine is possibly suitable when used for this duration. The long-term effects of use beyond the typical study periods have not been fully established in current research.

Q: Can I stop taking Neuroton suddenly, or do I need to taper off?

A: Official guidance indicates that the decision to discontinue or modify treatment with Neuroton should be made with the guidance of a healthcare professional. Product information advises against abruptly stopping certain types of medicines without professional oversight, as this may sometimes lead to a worsening of the treated condition.

Q: Why do some people report feeling tired when they first start Neuroton?

A: Official regulatory documents list fatigue (tiredness) as one of the possible undesirable effects reported under Nervous System Disorders. Other effects in this category, such as dizziness, may also contribute to a general feeling of low energy. These are recognized side effects that patients may experience, particularly when first starting the treatment.

Q: What foods or drinks should I avoid when taking Neuroton?

A: The official product label advises against the consumption of alcohol while taking this medication. Additionally, the drug should be taken at least two hours after taking any antacids that contain aluminum or magnesium, as these may affect how the drug is absorbed. Specific restrictions on ordinary food consumption are not typically listed in the product documentation.

Q: Does Neuroton affect my ability to drive or operate machinery?

A: Official safety documents list certain nervous system side effects, such as dizziness and headache. The presence of these effects suggests they may impact concentration, and caution is therefore advised when driving or operating machinery.

Q: Is Neuroton an antidepressant or an anti-anxiety medicine?

A: Regulatory authorities classify the active ingredient primarily as a nootropic and a psychostimulant. While some clinical research has explored the drug's potential involvement in conditions like depression or anxiety, these are not its stated primary classifications or approved indications.

Q: How does Neuroton work on the brain exactly?

A: Neuroton provides the essential chemical building blocks that the body needs for the biosynthesis of phospholipids. These phospholipids are vital structural components of the neuronal membranes (the outer layer of brain cells). By providing these materials, the medicine is described as protecting the structure of brain cells from breakdown and supporting their repair processes.

Q: Are there any known interactions between Neuroton and common supplements like St. John's Wort?

A: Official regulatory documents advise patients to exercise caution when combining the medication with other substances. While St. John's Wort may not be listed specifically, official product information includes a warning about certain herbal products or supplements that are known to cause drowsiness.

Q: Is Neuroton addictive or habit-forming?

A: The drug is not typically listed as a controlled substance by regulatory bodies. In fact, clinical research has investigated the drug's active ingredient for its potential role in treating dependence on other substances, which suggests that Neuroton itself is generally not the focus of abuse or habit-forming liability in official documents.

Q: What happens if I accidentally take two doses of Neuroton too close together?

A: Official documents indicate that the active ingredient has been observed to have a very low toxicity profile, even at doses higher than those typically prescribed. If the prescribed amount is exceeded, it is advisable to contact a healthcare provider for professional guidance.

Q: Are there specific symptoms that mean I should call a doctor while on Neuroton?

A: Regulatory information documents several potential adverse reactions, including severe changes in blood pressure (hypotension), significant skin rashes, or extreme gastrointestinal symptoms. If symptoms that are severe or concerning occur, it is appropriate to seek professional medical attention.

Q: Are there different strengths or formulations of Neuroton available?

A: Neuroton is supplied in a variety of pharmaceutical forms, including both a sterile aqueous solution for injection for parenteral use and oral forms. The oral preparations are available as solid tablets or a liquid oral solution. Specific dosages for these forms are defined in the regulatory labeling.

Q: Does taking Neuroton at a certain time of day matter?

A: The official dosing instructions state that the prescribed dose can be administered either once daily or divided into multiple doses throughout the day. For a single daily dose, the official labeling does not specify an optimal time of day (such as morning or evening) for administration.

Q: What kind of studies were done to get Neuroton approved?

A: The evidence base that supports the drug’s regulatory status includes data from Randomized Controlled Trials (RCTs). These studies are often summarized in systematic reviews which assess the body of evidence regarding its use for conditions like stroke and cognitive impairment.

Q: What is Neuroton typically used for in clinical settings?

A: The official product label details clinical uses such as supporting patients during the acute and recovery phases of a cerebral infarction (stroke). It is also used in the management of cognitive dysfunction related to various diseases and for cerebral insufficiency resulting from certain types of head trauma.

Q: Does Neuroton expire, and is it still safe after the expiration date?

A: Official disposal rules require that any expired or unused Neuroton must be discarded properly, often through authorized collection programs. The regulation is based on the principle that medicines have a specific shelf life, and their efficacy and quality may not be maintained after the expiration date.

Q: Is Neuroton considered a cognitive enhancer by the medical community?

A: Regulatory authorities classify the active ingredient, Citicoline, within the Nootropic class of medicines. The term nootropic is used to describe substances that are intended to support or enhance cognitive functions, such as memory and learning.

Q: How does the FDA classify Neuroton in terms of risk?

A: Regulatory portals categorize Neuroton as a Prescription Drug (Rx). The pharmacologic category is listed as a Psychostimulant and a Nootropic. Beyond specific warnings and contraindications detailed on the label, these portals do not assign a single, general 'risk' classification to the drug.

Q: Does research indicate that Neuroton is more effective for certain groups of people?

A: Official research summaries state that the findings from the trials are applicable only to the specific groups of people who were included in those studies. The available evidence is generally lacking in direct comparisons to definitively establish whether the medicine is more effective for one specific population versus another.

How should Neuroton be stored and disposed of?

How to Store and Dispose of Neuroton (Citicoline)

Neuroton (Citicoline) must be stored under specific environmental constraints to maintain stability, and disposal must follow official guidelines to ensure safety and environmental protection.


Official Storage Requirements

Condition Regulatory Mandate
Temperature Store below 30 C (e.g., at controlled room temperature).
Protection Keep in the original container or carton and protect from light and moisture.
Handling Do not refrigerate or freeze the injection solution.
Child Safety Must be kept out of the sight and reach of children.

Official Disposal Instructions

Expired or unused Neuroton must be managed according to national and local pharmaceutical waste regulations. Disposal instructions require that the product be discarded properly through an authorized collection program or disposal site. It is prohibited to dispose of this medicine via wastewater (flushing down the toilet) or general household trash, and single-use injectable ampoules must be discarded immediately after use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neuroton found in:

A-Z Index: